Form 4: Aura Biosciences SVP Sells Shares for Tax Obligations

Aura Biosciences' Senior VP of Finance, Amy Elazzouzi, sold 1,581 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Amy Elazzouzi, Senior Vice President, Finance of Aura Biosciences, Inc. (AURA), reported a transaction on January 20, 2026.
• The transaction involved the sale of 1,581 shares of Aura Biosciences common stock at a price of $4.86 per share.
• The sale was conducted to cover tax withholding obligations in connection with the vesting of restricted stock units.
• This sale was automatic and not at the discretion of the Reporting Person.
• Following this transaction, Amy Elazzouzi beneficially owns 84,081 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary sale to cover tax obligations from RSU vesting, which is a neutral event. It is not a sign of lack of confidence, nor a significant positive operational event.

Positives

• The transaction indicates the vesting of restricted stock units (RSUs), which is a form of executive compensation and a positive for the executive.

Negatives

• A reduction in the reporting person's direct beneficial ownership by 1,581 shares, although for a non-discretionary reason.

Risks

• Reduced direct beneficial ownership by a key executive, even if for a routine tax-related purpose, slightly decreases insider alignment.

Future Outlook

N/A

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or company-specific operational developments.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a small, non-discretionary sale for tax purposes, not indicative of a change in executive confidence.
• Management: A routine compensation event for the Senior VP of Finance, reflecting the vesting of equity awards.

Key Dates

Recommendation

The transaction is a non-discretionary sale of shares by a Senior Vice President to cover tax withholding obligations associated with the vesting of restricted stock units. This is a common and expected event in executive compensation and does not reflect a change in management's confidence or the company's fundamentals. Therefore, it provides no new information to warrant a change in investment stance.

Keywords

Aura Biosciences, AURA, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Amy Elazzouzi, Executive Compensation